Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by ORG Wealth Partners LLC

ORG Wealth Partners LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 83.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,401 shares of the biopharmaceutical company’s stock after purchasing an additional 1,089 shares during the period. ORG Wealth Partners LLC’s holdings in Gilead Sciences were worth $222,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. FMR LLC raised its position in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP boosted its stake in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after acquiring an additional 1,793,145 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the last quarter. Finally, Pacer Advisors Inc. grew its stake in Gilead Sciences by 24.7% in the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after purchasing an additional 1,564,792 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Wolfe Research started coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $87.00 to $113.00 in a report on Friday. Finally, Citigroup assumed coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 453,734 shares of company stock worth $41,902,086. 0.16% of the stock is owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.20 on Friday, reaching $88.94. 2,883,444 shares of the company traded hands, compared to its average volume of 5,201,311. The company’s 50 day moving average is $91.93 and its 200-day moving average is $83.06. The stock has a market capitalization of $110.84 billion, a PE ratio of 988.22, a P/E/G ratio of 2.24 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.46%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.